Type: Pancreatic cancer
Dr Sarah Hancock and the team are focusing on a weakness in pancreatic cancer linked to how cancer cells make and use fats to survive.
Prof Phillips and team are developing a new “two-in-one” RNA nanomedicine designed to tackle treatment resistance from two angles at the same time.
Improving the precision of this novel radiation technology could present a new treatment strategy for the 1,200 Australians diagnosed with locally advanced pancreatic cancer each year.
Professor Turner’s team aims to use cutting edge imaging approaches to shed light on how changes in nutrient metabolism and intracellular signalling contribute to two lethal characteristics of pancreatic cancer, namely chemoresistance and metastatic spread.
The team has developed a methodology to map the fibrotic tumour landscape, through real-time imaging of (i) the proximity of cancer cells to the host blood supply, (ii) their location with regards to the tumour invasive borders and (iii) the surrounding tissue compartment.
Associate Professor Marina Pajic and her team have identified a molecular pathway that controls communication between pancreatic cancer cells and stromal cells.
A/Prof Griffin will conduct pre-clinical tests of a much needed new combination treatment for patients with advanced pancreatic and bowel cancers.
Researchers will use cutting-edge imaging technology and lab models that mimic pancreatic cancer and watch tumour response to treatment.
Researchers will test a dual treatment approach that targets collagen production in pancreatic cancer tumours.
This innovative research could be a breakthrough in treating pancreatic cancer and improving survival outcomes.